Relapsed Congenital Vertical Talus Deformity: Outcomes of a Modified Minimally Invasive Method.

Abstract

To date, there is little literature that describes the optimal management for recurrent talonavicular subluxation after an initial attempt at surgical correction in children with congenital vertical talus (CVT). The purpose of this study is to evaluate the outcomes of a modified minimally invasive technique for the management of recurrent talonavicular subluxation in patients with CVT who have previously undergone at least 1 attempt at surgical correction. International Classification of Diseases codes were used to identify all patients with recurrent CVT deformity treated at our institution between 2006 and 2021. Retrospective chart review, including radiographic measurements of talocalcaneal and talar axis-first metatarsal base angles (TAMBA), was performed. Complications including recurrent talonavicular subluxation (lateral TAMBA >30 degrees) and hindfoot valgus (Anteroposterior talocalcaneal >40 degrees) were recorded. All statistical analysis was performed using an alpha of 0.05. Seventeen patients (24 feet) met all inclusion criteria, 9 (52.9%) of whom had underlying neurological syndromes. The average age at repeat treatment initiation was 26±17 months (range: 7 to 60 mo). Talonavicular reduction was achieved in all patients as evidenced by an average of 24.6 degrees and 54.9 degrees of correction in the Anteroposterior and lateral TAMBA, respectively. Radiographic recurrence of the talonavicular deformity was seen in 12 feet (50.0%). Six (25.0%) of the feet in 4 patients required a revision surgery, all of which occurred in patients with underlying syndromes ( P =0.02). The average patient-reported outcome measurement information system scores in the pain interference, mobility, and peer relations domains were 44.5±7.7, 44.1±13.5, and 54.8±9.9, respectively. Our midterm results suggest that many cases of recurrent CVT can be effectively managed through a modified minimally invasive revision surgery consistent with what has been described by Dobbs and colleagues for initial treatment. Further prospective studies with longer-term follow-up are warranted to confirm these findings. Level III.